Cooperative Groups and Collaborations
Mayo Clinic Cancer Center researchers collaborate regularly with scientists and clinicians in other organizations worldwide through cancer cooperative groups and a range of other programs.
Some of these efforts include:
- Many Mayo Clinic Cancer Center clinical trials are conducted under the auspices of one of the national clinical research groups sponsored by the National Cancer Institute (NCI), including the Alliance for Clinical Trials in Oncology.
- The Mayo Clinic Cancer Center serves as the research coordinating center for the Academic and Community Cancer Research United (ACCRU). ACCRU is a cancer clinical research network of academic institutions and community oncology practices that collaborates with industry partners to develop and conduct clinical trials and investigator-written studies.
- The Mayo Clinic Cancer Center coordinates the Phase 2 Consortium (P2C), a multicenter consortium specializing in phase II clinical trials of anti-cancer agents. Led by Charles Erlichman, M.D., P2C has 15 member institutions in the United States, Asia and Australia.
- The Mayo Clinic Cancer Center in Rochester co-hosts the Cancer Prevention Network (CPN). CPN, led by Paul J. Limburg, M.D., organizes, promotes and conducts cancer prevention research.
- The Pancreatic Cancer Genetic Epidemiology (PACGENE) Consortium, led by Gloria M. Petersen, Ph.D., is based in the Cancer Center. PACGENE is a group of NCI-funded individuals searching for the genetic underpinnings of pancreatic cancer.
- The Mayo Clinic Cancer Center participates in the NIH Pharmacogenetics Research Network research program. Led by Richard Weinshilboum, M.D., Mayo Clinic's project, "Pharmacogenetics of Phase II Drug Metabolizing Enzymes," is based on studies of the pharmacogenetics and pharmacogenomics of phase II drug-metabolizing enzymes.
- The Cancer Center is a member of GLIOGENE, an international consortium of familial brain tumor researchers. GLIOGENE hopes to learn more about possible genes related to brain tumor development and to identify a genetic link among family members of brain tumor patients.